SCS Capital Management LLC Invests $521,000 in Intuitive Surgical, Inc. $ISRG

Key Points

• SCS Capital Management LLC has invested $521,000 in Intuitive Surgical, acquiring 1,052 shares as reported in their recent SEC filing.
• Intuitive Surgical's earnings per share exceeded estimates at $2.19, and revenue for the last quarter was reported at $2.44 billion, a year-over-year increase of 21.4%.
• Analysts maintain a mixed outlook on Intuitive Surgical, with ratings ranging from "strong-buy" to "sell", and an average target price of $595.95.

SCS Capital Management LLC bought a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,052 shares of the medical equipment provider's stock, valued at approximately $521,000.

A number of other institutional investors have also recently modified their holdings of the stock. AlphaCore Capital LLC grew its stake in shares of Intuitive Surgical by 4.2% in the fourth quarter. AlphaCore Capital LLC now owns 451 shares of the medical equipment provider's stock worth $235,000 after acquiring an additional 18 shares during the last quarter. Second Line Capital LLC grew its stake in shares of Intuitive Surgical by 3.4% in the fourth quarter. Second Line Capital LLC now owns 578 shares of the medical equipment provider's stock worth $302,000 after acquiring an additional 19 shares during the last quarter. Crown Wealth Group LLC grew its stake in shares of Intuitive Surgical by 4.8% in the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after acquiring an additional 20 shares during the last quarter. FSM Wealth Advisors LLC grew its stake in shares of Intuitive Surgical by 3.8% in the first quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider's stock worth $270,000 after acquiring an additional 20 shares during the last quarter. Finally, CFO4Life Group LLC grew its stake in shares of Intuitive Surgical by 4.8% in the first quarter. CFO4Life Group LLC now owns 436 shares of the medical equipment provider's stock worth $216,000 after acquiring an additional 20 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Stock Performance

ISRG stock opened at $455.85 on Friday. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00. The business's 50-day moving average is $487.55 and its two-hundred day moving average is $509.57. The company has a market cap of $163.41 billion, a price-to-earnings ratio of 63.58, a P/E/G ratio of 4.72 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. During the same quarter in the prior year, the company earned $1.78 earnings per share. Intuitive Surgical's revenue was up 21.4% on a year-over-year basis. Equities analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other news, EVP Myriam Curet sold 4,500 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the transaction, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. This trade represents a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Amy L. Ladd sold 336 shares of the firm's stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total value of $157,956.96. Following the completion of the transaction, the director directly owned 1,074 shares in the company, valued at $504,898.14. This trade represents a 23.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,224 shares of company stock valued at $21,716,492 over the last quarter. 0.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Intuitive Surgical in a research report on Friday, August 22nd. Piper Sandler reaffirmed an "overweight" rating and set a $595.00 price objective (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Zacks Research cut Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Wall Street Zen raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Finally, Wells Fargo & Company increased their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the company an "overweight" rating in a research report on Wednesday, July 23rd. Thirteen analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.